HIV treatment in pregnancy
Part of Infections, Women’s health & pregnancy clinical trials.
This study tests whether a combination of two long-acting HIV medications (cabotegravir and rilpivirine), given as shots every month, is safe and works well for pregnant women who are already taking this treatment. It aims to keep the mother's HIV under control and protect the baby.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are pregnant with one baby and are between 10 and 23 weeks along.
- You have HIV and your viral load (amount of virus in your blood) is below 50 copies/mL.
- You have already started or will start the monthly shots of cabotegravir and rilpivirine before joining.
- You plan to deliver at a study hospital and stay nearby during the study.
- You have not had treatment failure or resistance to these HIV drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a two-drug HIV treatment combination (dolutegravir and lamivudine) for pregnant women who have never taken HIV medicine before. The goal is to see if this combination safely controls HIV during pregnancy and protects the baby.
This trial tests if switching to a long-acting injectable medication can help people with HIV who have trouble keeping their virus suppressed with daily pills. You would receive shots in the buttocks every few months instead of taking pills every day.
This study looks at how long an injectable HIV treatment (cabotegravir and rilpivirine) keeps working in people whose virus is already well controlled. It aims to see the real-world experience and how long patients stay on this treatment.
This trial studies whether a child can safely move from HIV medicine taken by mouth to long-acting monthly injections. It looks at keeping HIV levels suppressed (very low) and monitoring side effects and safety over time.
This study tests whether giving a combination of two lab-made antibodies (PGT121.414.LS and VRC07-523LS) to newborns exposed to HIV during pregnancy is safe and how the body processes them. It may help protect infants from getting HIV after birth.
This study gives very early, intensive HIV medicine to infants diagnosed with HIV and follows them closely to see if HIV can go into remission (stop being detectable without ongoing treatment). It may help families understand whether treating right after birth can change a child’s long-term HIV outlook.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.